ERBB2 and breast cancer: A central role of the HER2/PI3K/AKT/NF-kB signalling axis in immune responses to the HER2 oncodrive was confirmed by another study where activation of the HER2→ NF-κB signalling in the inflammatory milieu of IDC initiated and sustained the inflammation that supported the generation and maintenance of breast cancer stem cells (BCSC) [51].